The U.S. FDA has approved a new imaging agent for the detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. The agent, called 18F-DCFPyL (PyL), is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
PyL is approved for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
“We believe today’s approval is a game-changer for men facing prostate cancer,” says Jamie Bearse, CEO of ZERO—The End of Prostate Cancer, a patient advocacy group. “Having a diagnostic tool that allows doctors to see suspected metastatic or recurrent prostate cancer earlier, anywhere in the body, is a significant step forward and will have a tremendous impact on patients’ lives.”
PyL was initially developed by Martin Pomper, MD, PhD, director of nuclear medicine and molecular imaging at the Johns Hopkins University School of Medicine. The New Drug Application for the agent was filed in September 2020 and granted priority review by the FDA in December. Research supporting the approval of the agent came from two pivotal multicenter studies—the CONDOR study and the OSPREY study.
The agent is manufactured by Lantheus (PYLARIFY Injection) and will be widely available throughout the United States.